For the year ending 2025-12-31, CTMX has $151,566K in assets. $52,558K in debts. $12,667K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 12,667 | |||
| Short-term investments | 124,385 | |||
| Accounts receivable | 2,013 | |||
| Prepaid expenses and other current assets | 4,856 | |||
| Total current assets | 143,921 | |||
| Property and equipment, net | 1,304 | |||
| Intangible assets, net | 438 | |||
| Goodwill | 949 | |||
| Restricted cash | 1,527 | |||
| Operating lease right-of-use asset | 3,396 | |||
| Other assets | 31 | |||
| Total assets | 151,566 | |||
| Accounts payable | 1,301 | |||
| Accrued liabilities | 14,197 | |||
| Operating lease liabilities - short term | 4,240 | |||
| Deferred revenue, current portion | 26,877 | |||
| Total current liabilities | 46,615 | |||
| Deferred revenue, net of current portion | 1,590 | |||
| Operating lease liabilities - long term | 0 | |||
| Other long-term liabilities | 4,353 | |||
| Total liabilities | 52,558 | |||
| Common stock, 0.00001 par value 300,000,000 and 150,000,000 shares authorized, and 170,186,365 and 80,099,889 shares issued and outstanding at december 31, 2025 and 2024, respectively | 2 | |||
| Additional paid-in capital | 810,844 | |||
| Accumulated other comprehensive income | 111 | |||
| Accumulated deficit | -711,949 | |||
| Total stockholders' equity (deficit) | 99,008 | |||
| Total liabilities and stockholders' equity (deficit) | 151,566 | |||
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX)